Hormone receptor (HR)-positive / HER2-negative breast cancer has the highest incidence of all breast cancer subtypes. Treatment decisions are influenced by the stage of the disease, the patient’s menopausal status, resectability, the site of metastasis, and treatment history. The FDA’s approval of three CDK4/6 inhibitors in the metastatic setting (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) has changed physicians’ prescribing behavior and created new dynamics in treatment sequencing. This drug class has proven particularly effective when combined with hormonal agents. Additional effective treatments are the PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna) for metastatic germline BRCA-mutation-positive HER2-negative (including HR-positive) breast cancer and the PI3K inhibitor (Novartis’s Piqray) for advanced PIK3CA-mutation-positive HR-positive / HER2-negative disease.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 100 medical oncologists in the United States fielded in June 2022.
Key drugs: Ibrance, Kisqali, Verzenio, Lynparza, Piqray, Talzenna, Afinitor, fulvestrant.